ASTH

Rating neutralTentativeAI MemoPost-earnings T+3

Astrana Health

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Strong Q2 print and higher FY2026 EBITDA guidance • 2026-08-06

Base target: $38 / p=50% prob

Biggest risk

The company still needs to demonstrate durable medical-cost performance and operating leverage as it scales. Care Delivery remained loss-making at the segment operating level in Q2, and management plans to reinvest a substantial portion of first-half outperformance into growth. [#SEC-8K-2026-08-06]

Invalidation

Break below $27 or thesis failure.

What would change my mind?

The Q2 filing confirms strong growth, cash generation, and adjusted EPS expansion, while higher FY2026 EBITDA guidance improves forward visibility. Continued full-risk membership growth, shared-savings performance, and deleveraging could support multiple expansion. [#SEC-8K-2026-08-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-08

Base target

$38

p=50%

Bull target

$52

p=25%

Bear target

$27

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q3 execution against updated operating targets
Scaling full-risk value-based care
The Q2 filing confirms strong growth, cash generation, and adjusted EPS expansion, while higher FY2026 EBITDA guidance improves forward visibility.

BearKey bullets

Care Delivery reported a segment operating loss in Q2 despite strong revenue growth, leaving execution and reinvestment risk.
Expansion of full-risk arrangements requires sustained medical-cost control, membership growth, and contract execution.
FY2026 guidance remains assumption-dependent, and management indicated that part of first-half outperformance will be reinvested in growth opportunities.

WatchKey bullets

Strong Q2 print and higher FY2026 EBITDA guidance

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $38 (p=50%)

Target spread vs base: +37% / -29%

Scenario probabilities

Bull Target: $52 (p=25%)Base Target: $38 (p=50%)Bear Target: $27 (p=25%)

Commentary

The official Q2 filing provides a clearly positive operating narrative through strong year-over-year results and higher adjusted EBITDA guidance. A secondary MarketBeat earnings page displayed an August 7 close of $35.76, up 4.78%, followed by an extended-hours quote of $35.05, down 1.99%, suggesting a positive regular-session reaction with some after-hours giveback. The same page listed provisional consensus references but no actual beat/miss fields. No verified post-print analyst target revisions are available, and social coverage is unavailable; the thesis remains a cautious hold rather than a high-confidence upgrade.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q3 execution against updated operating targets
Scaling full-risk value-based care

Scenarios

Bull Target (Scenario probability)

$52 / p=25% prob

Base Target (Scenario probability)

$38 / p=50% prob

Bear Target (Scenario probability)

$27 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.75

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-06
Strong Q2 print and higher FY2026 EBITDA guidance
Q2 revenue rose 49% year over year to $972.5 million, adjusted EBITDA rose 43% to $68.9 million, adjusted EPS rose 45% to $0.80, and management raised FY2026 adjusted EBITDA guidance to $255-$280 million while reaffirming revenue and free-cash-flow guidance. One secondary estimate page listed $0.34 EPS consensus and $985.62 million expected revenue, but its actual fields were unavailable; the earnings surprise is therefore only provisional. [#SEC-8K-2026-08-06]
Prob 88.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Q3 execution against updated operating targets
2026-09-30
Q3 guidance of $1.00-$1.03 billion revenue and $72.5-$77.5 million adjusted EBITDA provides the next dated test of growth, margin conversion, and execution after the Q2 report. [#SEC-8K-2026-08-06]
Prob 65% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

Scaling full-risk value-based care
2026-12-31
New Hawaii and Texas agreements, including approximately 3,000 additional Texas Medicare Advantage professional-risk lives, plus $120.4 million of gross shared savings generated by affiliated ACOs, support a longer-term scaling thesis. Multiple quarters of execution are still required. [#SEC-8K-2026-08-06]
Prob 55% • Move 20% • Priced-in 35%

Risks

Care Delivery reported a segment operating loss in Q2 despite strong revenue growth, leaving execution and reinvestment risk.
Expansion of full-risk arrangements requires sustained medical-cost control, membership growth, and contract execution.
FY2026 guidance remains assumption-dependent, and management indicated that part of first-half outperformance will be reinvested in growth opportunities.
The earnings surprise comparison remains provisional because the packet lacks consensus estimates and the secondary estimate source did not populate actual beat/miss fields.
The regular-session reaction was positive, but the reported after-hours price moved lower, leaving the durability of the post-print reaction uncertain.

Peers

Symbol	Summary
ARDT	The closest candidate with a somewhat more comparable healthcare-services orientation, but its hospital operating model remains a loose comparator for Astrana's physician-network and value-based-care platform.
INSP	Broad same-sector and similar-market-cap reference only; its medical-device economics differ materially from Astrana's risk-bearing healthcare-services model.
LMAT	Broad same-sector and similar-market-cap reference only; its vascular-device business is not a direct operating or valuation peer. The packet does not establish two strong direct comparators.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ARDT

The closest candidate with a somewhat more comparable healthcare-services orientation, but its hospital operating model remains a loose comparator for Astrana's physician-network and value-based-care platform.

INSP

Broad same-sector and similar-market-cap reference only; its medical-device economics differ materially from Astrana's risk-bearing healthcare-services model.

LMAT

Broad same-sector and similar-market-cap reference only; its vascular-device business is not a direct operating or valuation peer. The packet does not establish two strong direct comparators.